An orally bioavailable selective CK2 inhibitor, CX-4945 (silmitasertib), reduces MGMT expression by blocking β-catenin expression in medulloblastoma and sensitized tumor cells to TMZ [108]. Here, MGMT is linked to medulloblastoma.